Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cytokinetics, Inc.    CYTK

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

CYTOKINETICS : Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/19/2011 | 02:40pm CEST
Results from These Trials Form the Basis For Ongoing Phase IIb Activities in Collaboration with Amgen

South San Francisco, CA - August 19, 2011

omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet. These two manuscripts present data regarding the safety, tolerability, pharmacokinetics and pharmacodynamic effects of this investigational drug candidate from a Phase I first-time-in-humans clinical trial in healthy volunteers and a Phase IIa clinical trial in stable heart failure patients, each sponsored by Cytokinetics. Together, these publications provide evidence for the translation into humans of this unique mechanistic approach to activating cardiac muscle contractility and support the further development of omecamtiv mecarbil as a potential treatment for heart failure. Amgen Inc. holds an exclusive, worldwide (excluding Japan) license to omecamtiv mecarbil and related compounds, subject to specified development and commercialization participation rights of Cytokinetics.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CYTOKINETICS, INC.
06/23 Cytokinetics Announces Presentations at the Cure SMA 2017 Annual SMA Conferen..
06/13 Cytokinetics to Participate in Panel on Neuromuscular Disorders at the JMP Se..
05/19 CYTOKINETICS, INCORPORATED (NASDAQ : CYTK) Files An 8-K Submission of Matters to..
05/19 CYTOKINETICS INC : Submission of Matters to a Vote of Security Holders (form 8-K..
05/16 CYTOKINETICS : CYTK) Receives FDA Orphan Drug Designation for CK-2127107 for Tre..
05/15 CYTOKINETICS INC : Other Events (form 8-K)
05/15 Cytokinetics Announces Orphan Drug Designation for CK-2127107 for the Treatme..
05/11 Cytokinetics to Hold Annual Meeting of Stockholders
05/10 CYTOKINETICS : Announces Pricing of Public Offering of Common Stock
05/09 CYTOKINETICS, INCORPORATED (NASDAQ : CYTK) Files An 8-K Other Events
More news
Sector news : Bio Therapeutic Drugs
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Bio Therapeutic Drugs
Advertisement
Financials ($)
Sales 2017 28,0 M
EBIT 2017 -96,4 M
Net income 2017 -103 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 25,1x
Capi. / Sales 2018 12,6x
Capitalization 703 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 21,7 $
Spread / Average Target 50%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert I. Blum President, Chief Executive Officer & Director
L. Patrick Gage Chairman
Barabari Sharon A. Surrey Chief Financial Officer, Secretary & Executive VP
Andrew A. Wolff Chief Medical Officer & Senior Vice President
Fady Ibraham Malik Executive Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CYTOKINETICS, INC.703
AMGEN17.98%126 856
CELGENE CORPORATION16.03%104 873
GILEAD SCIENCES-1.52%92 150
REGENERON PHARMACEUTIC..43.43%54 987
VERTEX PHARMACEUTICALS83.97%33 251
More Results